Moderna Stock

Moderna Operating Cash Flow

The Operating Cash Flow of Moderna (MRNA) as of Aug 9, 2026 is -1.87 B USD. In the previous year, Operating Cash Flow was -3.00 B USD — a change of -37.65% (higher).

Operating Cash Flow

-1.87 BUSD

YoY

-37.65%

Last updated:

Operating Cash Flow of Moderna is 2026 -1.87 B USD. Operating Cash Flow of Moderna was 2025 -3.00 B USD. It decreases by -37.65% higher compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

Operating Cash Flow of Moderna is -1.87 B USD in 2026.

Operating Cash Flow of Moderna changed from -3.00 B USD to -1.87 B USD, representing a -37.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Moderna since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Moderna historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Moderna

All Key Metrics — Moderna